The increase in revenues primarily reflects gains in sales of the company’s products and services from its API, contract research and manufacturing and peptides synthesis businesses.
Neuland Labs CEO Sucheth Davuluri said a notable event during the first quarter was Neuland’s new commercial-scale peptide manufacturing service at a symposium for peptide experts from around the world.
"This expanded service, which provides customers rapid access to commercial quantities of affordable, high quality peptides," Davuluri said.